RxDoctor Payments Data

Jair Munoz Mendoza, MD

Nephrology · Miami, FLNPI 1174752877

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by OPKO Pharmaceuticals, LLC at 36.5% of the total. Reporting peaked in 2019 at $336 and has fallen 86.9% since, to $44 in 2025. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.

$642in general payments, 2019–2025

Across 8 payments — averaging $80.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$234
  • Bayer$151
  • Baxter Healthcare$123
  • Calliditas Therapeutics US Inc.$66
  • Novo Nordisk$44
  • Akebia Therapeutics Inc$25
$12,140in research payments, 2019–2025

Across 2 payments — averaging $6070.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ardelyx, Inc.$12K

What the payments were for

  • Food & beverage$61796%
  • Education$254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$642 in reported general payments places this provider in the 30th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024
$168,512
Medicare patients
306
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide17$27,398
FarxigaDapagliflozin Propanediol13$7,449
ClinisolParenteral Amino Acid 15% No.512$3,938
ProsolParenteral Amino Acid 20% No.115$3,168
ClinolipidFat Emulsion/Olive/Soy/Phospho13$2,273
Bumetanide17$1,001
Nifedipine ErNifedipine32$720
Chlorthalidone20$305
Furosemide28$247
Amlodipine Besylate39$238
Doxazosin Mesylate21$234
Losartan Potassium16$64
Lisinopril16$51

Paid to pharmacies, not to this prescriber.

Other nephrology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →